S ynthetic biology uses engineering principles to introduce desirable functionalities into biological systems by rewiring standardized biological parts in a rational and predictable manner 1, 2 . By implementing gene circuits that interfere with pathological responses in metabolic and autoimmune diseases or tumor progression, the discipline has paved the way for harnessing therapeutic cell implants in vivo 3 . Such devices can also detect the onset of microbial infections by scoring pathogenic markers released from damaged tissue 4 . Synthetic-biological approaches have also been utilized in the discovery of antimicrobials 5 . However, bacterial drug resistance is becoming an increasing global health concern, and new treatment alternatives to antibiotics, that reduce bacterial virulence without applying selective pressure on essential pathways are urgently needed 6 .
An attractive strategy for this purpose is to target non-essential bacterial communication via diffusible signaling molecules called autoinducers, which synchronize collective bacterial behavior 7 . The increase of autoinducer levels with increasing bacterial population density orchestrates population-wide gene expression through a process called quorum sensing 8 . This enables unicellular bacteria to function as a multicellular-like organism, and synchronizes behaviors, such as pathogenicity, motility, biofilm formation, and antibiotic resistance 9, 10 . Many prokaryotes have evolved signals for interspecies or host interactions 11 , but the family of interconverting autoinducer-2 (AI-2) molecules derived from 4,5-dihydroxy-2,3-pentanedione appears almost ubiquitously as a communication signaling system throughout the bacterial kingdom. AI-2 has been shown to promote the treatment of Vibrio cholerae infections 10 and microbial biofilms 12, 13 , and also helps in reestablishing a healthy gut microbiome by favoring the expansion of Firmicutes over Bacteroidetes 14 populations even in the presence of commensal AI-2 secreting bacteria without imposing drastic selection pressure 6 . Therefore, in order to develop a synthetic biology-based device to mediate cell-based anti-infective activity, we selected AI-2 as the effector component. However, it is important to keep in mind that in other bacteria AI-2 can also have consequences that can promote virulence, rather than attenuating it, such as autoaggregation of Escherichia coli 15 and the release of phage by Enterococcus faecalis 16 . Thus, this aspect needs to be considered when targeting quorum sensing.
On the other hand, for the detection of infection, we focused on cell-surface formyl peptide receptors (FPR) 17 that detect invading pathogens releasing formyl peptides such as N-formylmethionyl-leucyl phenylalanine (fMLF). Only the most potent amongst the three members of the human FPR receptor family, FPR1, monitors the presence of nanomolar concentrations of chemotactic N-formylated peptides 18 , and is therefore suitable for early-stage detection of infections. Formylated peptides are ubiquitous by-products of prokaryotic protein translation released by invading microorganisms, and progressively guide phagocytes to the site of infection or inflammation 19 . Formylated peptides serve as signal peptides in bacteria and are released after translocation of the carrier protein across the cytoplasmic membrane 17 . Over 300 bacterial species have been identified to produce formylated peptides with variable sequence and length which activate human FPR1 at low nanomolar concentrations 17 . The prototypic tripeptide fMLF 20 produced by opportunistic E. coli and the tetrapeptide N-formyl-Met-Ile-Phe-Leu (fMIFL) released by Staphylococcus aureus 21 are among the most potent FPR1 agonists know today. While N-terminal fMet most likely acts as protein degradation signal in bacteria 22 , it has not been reported in unicellular eukaryotes or in higher organisms outside mitochondria or damaged tissue 19 .
Because native chemotaxis-associated G-protein-coupled receptors expressed by human neutrophils 23 specifically interact with diffusible pathogen-derived formylated peptides, we hypothesized that this biosensor/biomarker combination could be engineered to interface with a broad range of potential infections. Further, we considered that a synthetic formyl peptide sensor (FPS) module could be coupled with an AI-2 release module that would act upon infections by autonomously reprogramming bacterial communication. The presence of any bacteria in the bloodstream represents an acute life-threatening situation (e.g., sepsis), which may be attenuated by the secretion of quorum-sensing molecules. Implanted designer cells monitoring the presence of bacteria via circulating biomarkers such as formyl peptides ensure that AI-2 will be released at the right time and place. Like for other synthetic biology-inspired designer cellbased proof-of-concept therapies 24 , the real therapeutic setting will be based on subcutaneous implantation of encapsulated designer cells. Encapsulation protects the designer cells from the host immune system as well as the host from the designer cells for months 25 and enables continuous oxygen supply by promoting autovascularization 25, 26 , the connection of the designer cells to the bloodstream of the patient.
Based on the above ideas, we report here the design, development and evaluation of a synthetic biology-inspired gene circuit, which we call microbial-control device, that bridges the interface gap between mammalian cells and microbes by utilizing cell-derived quorum-sensing molecules to autonomously regulate microbial behaviors, and in some bacteria, inhibit virulence. Essentially, host cells can be programmed to control infectious organisms. When challenged with autoinducer-responsive pathogens, microbial-control-engineered cells detect microbial peptides with high sensitivity and secrete AI-2 to control quorum-sensing-related behavior and reduce microbial biofilm formation of several clinically relevant species. Given the plethora of bacterial species endowed with AI-2 signaling systems, we believe this microbial-control device represents a promising prototype of cell-based anti-infective systems that mimic hostmicrobe cross-talk.
while luxS expression, either constitutive or under control of a synthetic P Ca2 promoter, guides the conversion of the SRH intermediate into a set of interconverting AI-2 signaling molecules 31, 32 . Rewiring of the FPS − derived signaling cascade to the Ca 2+ -driven synthetic promoter links both modules, completing the microbial-control circuit.
Validation of the pathogen-detecting FPS. We initially established and optimized the components for the sensor unit (FPS). For this purpose, we connected constitutively expressed FPR1 receptors (P SV40 /P hEF1α -FPR1-pA, pFS98/pFS115) to the G α16 adapter protein (P hCMV /P SV40 -Gα16-pA; pcDNA3.1-Gα16/ pFS102) under control of fine-tuned promoter strengths and in a defined ratio, and linked them to Ca 2+ -dependent expression of SEAP (human placental secreted alkaline phosphatase; P Ca2 -SEAP-pA, pYL1) or cytosolic Citrine, an enhanced YFP (P Ca2 -Citrine-pA, pFS220) reporter (Fig. 2a) . Cotransfection of HEK-293 cells with all three components of the FPS network (pFS98/pFS102/pYL1) validated formyl peptide-dependent target gene expression (Fig. 2b) . FPS-activating fMLF levels are in the physiologically relevant concentration range, since fMLF levels over 50 nM efficiently stimulate FPR1 or the innate immune response 33 .
As the reporter configuration featuring a combination of CRE, SRE and NFAT response elements upstream of a minimal TATA-box promoter (pYL1) provided a superior induction profile and higher maximum formyl peptide-dependent expression levels than simple P NFAT -driven promoters (pMX57), we used the former as the preferred reporter scaffold for follow-up experiments. The FPS module demonstrated functionality in different FPR1/G α16 -cotransfected mammalian cell lines such as human mesenchymal stem cells (hMSC-TERT), human alveolar epithelial cells (A549) and colorectal epithelial cells (Caco-2) (Fig. 2c) , suggesting broad applicability of the synthetic bacterial detection cascade with altered induction profiles among different cell lines 34 . Variations in the overall performance of the FPS module in different cell types reflects the combinatorial impact of endogenous Gα levels, ectopic FPR1 expression 35 , the NFAT transcription factor repertoire, transfection efficiency (Fig. 2d) , and the protein secretion capacity of the specific cell types. Stronger promoters driving higher FPR1 and Gα16 expression levels increased the performance of the FPS module in Caco-2 cells ( Supplementary  Fig. 1a ) and hMSCs ( Supplementary Fig. 1b) .
Additionally, fine-tuning of the relative FPR1/G α16 expression levels substantially increased FPS performance ( Supplementary  Fig. 1c) , in particular when G α16 levels exceeded those of other G-proteins such as G αi2 (Supplementary Fig. 1d ). Since HEK-293 showed the best microbial peptide-triggered expression performance, this cell line was chosen for subsequent experiments.
Further characterization of the FPS in HEK-293 cell populations demonstrated that the sensor circuit featuring the human FPR1 receptor (pFS98/pFS102) robustly responded with low nanomolar sensitivity (EC 50 = 2 nM) to a wide range of formyl peptide concentrations, while a receptor variant engineered for decreased internalization and desensitization 36 (FPR1ΔST; P SV40 -FPR1ΔST-pA/pFS222) displayed a comparable dose-response profile (EC 50 = 4 nM) combined with a broader dynamic range (Fig. 3a) . As the FPS configuration featuring FPR1 (pFS98) demonstrated the highest sensitivity based on its effective concentration (EC 50 ) in HEK-293 combined with best fold induction in the nanomolar fMLF range, this receptor was selected for follow-up experiments.
To assess whether stable chromosomal integration of the FPS components ( Supplementary Fig. 2a ) into HEK-293 cells would allow long-term stability and responsiveness of the FPS network, we selected stable FPS SEAP36 monoclonal cell populations and profiled reporter gene expression after induction with low amounts of fMLF (10 nM) to favor the identification of highly sensitive clones ( Supplementary Fig. 2b ). The monoclonal cell population FPS SEAP36.7 (FPS SEAP36 clone 7) was the best-performing formyl peptide-responsive transgenic cell line showing high sensitivity (EC 50 = 1 nM) and SEAP induction factor (9-fold; Supplementary Fig. 2c ), full reversibility characterized by sequential ON/OFF switches following addition and withdrawal of formylated peptides (Fig. 3b) as well as long-term sensitivity 24 to microbial formylated peptides for a testing period of over 3 weeks (Supplementary Fig. 2d ). High sensitivity of the FPS to the microbial chemoattractant fMLF and a rapid output profile were confirmed by real-time monitoring of the intracellular fluorescent reporter Citrine in pFS98/pFS102/pFS220-cotransfected (FPS Citrine ) cell populations (Fig. 3c) . These results indicated that the FPS delivers a rapid response within 3 h after detection of formylated peptides (Fig. 3d) , which is considered a fast transcription response 37, 38 and would allow the detection of pathogens at an early phase of infection.
In addition to E. coli-derived fMLF, FPS SEAP -engineered cells also reliably recognized the N-formyl peptide fMIFL, a prototypic peptide released from S. aureus, while the corresponding non-formylated tripeptide t-butyloxycarbonyl-MLF (BocMLF), a competitive FPR1 antagonist 39 , failed to activate FPR1 14 (Fig. 3e) (Fig. 3f) . We observed that SEAP levels were exclusively increased by supernatants obtained from prokaryotes and C. albicans. In contrast Saccharomyces cerevisiae, which do not produce formylated peptides 41 and therefore served as negative control, did not induce SEAP expression ( Supplementary Fig. 3a) , which implies sensitivity of the FPS to N-formyl peptides at the concentrations found in nature (Supplementary Table 2 ). Bacterial cell densities used to produce the formylated peptide-containing culture supernatants (10 6 CFUs/ml) are were cotransfected with the G protein-coupled receptor FPR1 (P SV40 -FPR1-pA, pFS98), the G Protein G α16 (P SV40 -G α16 -pA, pFS102) and a calcium-responsive reporter, (P Ca2 -SEAP-pA, pYL1) or (P NFAT3 -SEAP-pA, pMX57), to produce SEAP in response to fMLF, in contrast to control cells lacking either the calcium pathway-rerouting Gα 16 or the FPR1 sensory module. c Formyl peptide-induced SEAP expression in different cell lines. HeLa, COS-7 and HEK-293 were cotransfected with the FPR1-encoding expression vector (P SV40 -FPR1-pA, pFS98), the G α16 -encoding expression vector (P SV40 -G α16 -pA, pFS102) and the P Ca2 -driven SEAP reporter plasmid (P Ca2 -SEAP-pA, pYL1), while hMSC-TERT, A549, Caco-2 and HT-1080 were engineered with the FPR1-encoding expression vector featuring the human elongation factor 1 alpha (P EFIα ) promoter (P EFIα -FPR1-pA, pFS115), the P hCMV -driven Gα 16 expression vector (P hCMV -Gα 16 -pA , pcDNA3.1-G α16 ), together with the reporter plasmid (pYL1). Cells were grown in the presence or absence of N-formyl peptide, and SEAP levels were profiled in the culture supernatant after 24 h. Characterization of the formyl peptide transgene switch. a Formylated peptide sensitivity and adjustability of the FPS in HEK-293 cells cotransfected with pFS102 (P SV40 -G α16 -pA) plus pYL1 (P Ca2 -SEAP-pA) and either pFS98 (P SV40 -FPR1-pA), pFS222 (P SV40 -FPR1ΔST-pA) or with pFS29 (P SV40 -mCherrypA). SEAP expression was quantified after 24 h. The data points were fitted using a sigmoidal dose-response curve. b Reversibility of formyl peptideresponsive SEAP expression assessed by cultivating stable FPS SEAP36.7 cells for 72 h while alternating the fMLF levels (0/10 nM) every 24 h and recurrent fMLF exposure for 1 h. Arrows indicate medium change. c Fluorescence micrographs of FPS Citrine (pFS98/pFS102/pFS220) and iRFP670 (P hCMV -iRFP670-pA, pMM581)-cotransfected cell populations cultivated for 24 h in the presence of different concentrations of fMLF. Scale bar = 100 μm. similar to those reported for in vivo conditions 43, 44 . E. coli culture supernatants activated the FPS system to a high level since E. coliderived fMLF is one of the most potent FPR1 agonists 20 ( Fig. 3f) . HEK-293's endogenous G αq -coupled receptors that also signal through the Ca 2+ -dependent pathway did not interfere with the FPS module at physiological norepinephrine and acetylcholine concentrations ( Supplementary Fig. 3b ), confirming previous results with other important signaling pathways 38 . Additionally, the FPS module was neither substantially activated by mitochondria-derived formylated peptides released by cell debris containing ( Supplementary Fig. 3c ) nor by human serum ( Supplementary Fig. 3d ). Control experiments showed that the cell viability was not affected by the presence of formyl peptides ( Supplementary Fig. 3e, f) .
C . a l b i c a n s P . a e r u g i n o s a V . h a r v e y i E . c o l i S . p n e u m o n i a e S . a u r e u s S . e n t e r i c a E . f a e c a l i s L . i n n o c u a B . c e r e u s
A mammalian AI-2 designer biosynthesis pathway. To automatically link the onset of infection to an output that modulates or counteracts microbial behavior, we then implemented an AI-2 production platform seamlessly integrating with human cellular metabolism. The AI-2 unit harbors a synthetic metabolic pathway that produces and secretes the common quorum-sensing molecule AI-2 within mammalian cells (Fig. 4a) . Based on the well-described E. coli AI-2 biosynthesis pathway 31 , we speculated that ectopic overexpression of human codon-optimized mtaN would partially by-pass the human endogenous methylation cycle ( Supplementary Fig. 4a ) by converting the waste product S-adenosylhomocysteine (SAH) into SRH. Preventing SRH accumulation by additional ectopic expression of human-codonoptimized AI-2 synthase (luxS) should lead to production of AI-2 via 4,5-dihydroxypentane-2,3-dione (DPD) as an intermediate 45 .
Indeed, HEK-293 cells co-transfected with the E. coli-derived enzymes MTAN (P hCMV -MTAN-pA, pFS84) and LuxS (P hCMV -LuxS-pA, pFS83) extracellularly accumulated bioactive AI-2. Heterologous AI-2 production was profiled by various specific V. harveyi AI-2 reporter strains, including the two most reliable AI-2 V. harveyi sensor strains that presently exist, BB170 and MM32. BB170 harbors a knockout in the AI-1 sensor to prevent interference by the unrelated AI-1 and MM32 contains an additional AI-2 production deficiency. The control strain JMH626 (sensitive only to the Vibrio cholerae autoinducer CAI-1) excluded the possibility of unspecific AI-2 reporter activation (Fig. 4b ) 46 . The two-component AI-2 production platform thus provides efficient autoinducer synthesis in pFS83/pFS84-cotransfected HEK-293 cells (Fig. 4b) , in sharp contrast to cells harboring only the individual components (Fig. 4c ).
Mammalian cells are very good heterologous protein producers, hence their importance for the production of bioparmaceuticals, but are very poor small-molecule producers 47 . Therefore, we have tested a variety of standard mammalian cell lines (HeLa, hMSC, HT-1080), including cell types that are targets for bacterial infections (A549, Caco-2), to evaluate the best-in-class small-molecule producer that can synthesize AI-2 at the highest possible level. AI-2 secretion from different mammalian cell lines co-transfected with constitutive AI-2 expression vectors (P hCMV -LuxS-eYFP-pA, pFS169) and MTAN-eYFP (P hCMV -MTAN-eYFP-pA, pFS170) confirmed that HEK-293 cells, which already exhibited the best FPS induction profile, also efficiently secreted AI-2 into the culture medium (Fig. 4d) . Expression of fluorescent AI-2 converting enzymes was observed in all AI-2 positive cell lines (Fig. 4e) . The overall AI-2 production level results from a combination of (i) transfection efficiency of plasmids encoding the AI-2-biosynthetic enzymes, (ii) the expression levels of AI-2-biosynthetic enzymes, (iii) activity and metabolic impact of AI-2-synthesizing enzymes in the heterologous mammalian host, (iv) availability of the substrate SAH and cofactors in the mammalian cytosol and (v) the secretion of the heterologous AI-2 through the plasma membrane.
Neither metabolic engineering with AI-2-biosynthetic enzymes ( Supplementary Fig. 4b ) nor the addition of AI-2 to cultured cells ( Supplementary Fig. 4c ) did affect the overall cell viability. Ectopic expression of intracellular AI-2-biosynthetic enzymes ( Supplementary Fig. 4d ) did not impact cell morphology (Supplementary Fig. 4e ). AI-2 activity in (pFS83/pFS84)-transgenic HEK-293 cells was already detectable within 30 min in culture supernatants based on V. harveyi (BB170) bioluminescence ( Supplementary Fig. 5a ), and after 24 h cellular AI-2 release reached micromolar levels (2 µM) ( Supplementary Fig. 5b ), which lies within the lower autoinducer concentration range commonly found in bacteria such as E. coli 48 during logarithmic growth ( Supplementary Fig. 5c ). A selected stable HEK-293 AI-2 monoclonal cell population with stable chromosomal integration of both mtaN and luxS-eyfp ( Supplementary Fig. 6a ), combining efficient AI-2 secretion from the previously characterized transient AI-2 module and the highest production level of AI-2, termed HEK-293 AI-2(12) (clone number 12), was used in further experiments (Supplementary Fig. 6b ).
Cell-based validation of quorum-sensing inhibitors. We further aimed to harness cellular AI-2 production from the monoclonal population to evaluate AI-2 biosynthesis inhibitors in a cell-based assay; previously, only bacterial or biochemical assays have been available for this purpose 49 . In principle, human cell-based assays provide much more information than simple mechanistic MTAN inhibition which is highly relevant for further drug development: 5 (i) Non-cytotoxicity of the compound to human cells, (ii) bioavailability of compounds such as diffusion into human cells to target intracellular pathogens and (iii) the absence of off-target effects towards the human MTA phosphorylase 50 . The cell-based assay for detection of AI-2 biosynthesis inhibitors targeting LuxS or MTAN combines the HEK-293 AI-2(12) AI-2 module with the AI-2 sensing abilities of V. harveyi (LuxS -, MM32) in a single well of a high-throughput-compatible 96-well plate (Fig. 4f) . We tested several rationally designed transition state analogs of AI-2 biosynthetic enzymes that showed the strongest inhibition of LuxS 51 or MTAN in vitro, including a compound that outperforms natural AI-2 synthesis inhibitors 52 . Challenging HEK-293 with the first rationally designed compound targeting MTAN revealed that But-DADMe-ImmA 53 is a specific inhibitor with an IC 50 value of 7.7 nM (Fig. 4g ). This cell-permeable compound was bioavailable, non-cytotoxic ( Supplementary  Fig. 7a, b) while it substantially reduced quorum-sensingassociated characteristics of V. harveyi without compromising the pathogen's capability to detect AI-2 ( Supplementary Fig. 7c ). The assay could be further extended to evaluate a small set of rationally-designed LuxS inhibitors among which SK2-93 (IC 50 = 3.4 µM) 51 ( Supplementary Fig. 8a ) showed the best characteristics followed by SK2-92 (IC 50 = 73 µM) 54 ( Supplementary  Fig. 8b ). Targeting either LuxS, MTAN or both building blocks of the AI-2 module resulted in AI-2 release with NOR logic gate behavior and hence validated sequential activity of the AI-2 biosynthesis components ( Supplementary Fig. 8c ).
Programming quorum-sensing interference with human pathogens. After validation and optimization of the first module for high formyl peptide sensitivity and the second module for maximum AI-2 secretion in human and primate cells, we assembled the microbial-control circuit by docking the FPS to the AI-2 module. Cotransfection of HEK-293 cells with the FPS components (pFS98/pFS102) in combination with a Ca 2+ -dependent version of the AI-2 module harboring P Ca2 -luxSpA (pFS186) linked to constitutively expressed mtaN (pFS84) afforded programmable microbial-control cell populations (Fig. 5a) . We confirmed that cells engineered with the microbialcontrol device (pFS98/pFS102/pFS84/pFS186) detected nanomolar levels of N-formyl peptide and responded by dynamically adjusting cellular AI-2 release in the sub-micromolar range, as shown by up to 330-fold bioluminescence induction of V. harveyi (Fig. 5b) .
AI-2 predominantly impacts bacteria during their logarithmic growth. Therefore, we also confirmed dynamic AI-2 release in response to increasing induction pulse durations at different physiological fMLF concentrations: high formyl peptide levels quickly turned on AI-2 production, whereas lower levels required a longer induction pulse period to generate significant AI-2 activity in the extracellular environment (Fig. 5c) . The microbialcontrol device was also programmable inside a variety of human cells, confirming the broad applicability of the system (Supplementary Fig. 9a ). Although fMLF-triggered AI-2 production may appear moderate in some cell types, the absolute AI-2 levels produced by all cell types are within the clinically effective range 55, 56 . Since HEK-293 showed the best overall fMLFmediated control performance they were used as parental cell type for all follow-up experiments. Currently, HEK-293 cells emerge as the optimal parental cell line for the design of synthetic biology-based circuits because of their increased production capacity, transfection rate and cultivation robustness 24, 26 . We confirmed this notion by generating monoclonal penta-transgenic HEK-293-derived FPS AI2 cell populations ( Supplementary Fig. 9b ) whose fMLF-triggered AI-2 production was profiled over a wide fMLF concentration range ( Supplementary Fig. 9c ) and remained robust for a testing period of over 3 weeks ( Supplementary  Fig. 9d ).
To verify the functionality of the microbial-control device and to assess whether the microbial-control two-way communication system indeed modifies quorum-sensing-controlled pathogenic behavior in an infection-like environment, we first profiled bacterial quorum-sensing-related behavior in the presence of microbial-control-engineered cells. To demonstrate remote control of collective bacterial behavior, we chose the AI-2-deficient quorum-sensing variant of the model organism V. harveyi (luxS -) and a co-incubation model featuring Transwell permeable supports, which allows bacterial formyl peptides and signaling molecules such as AI-2 (or any secretable molecules) from mammalian cells to pass. The small membrane pore size (0.3 µm) allows HEK-293-derived microbial-control cells to communicate with bacteria, while shielding them from direct pathogen contact (Fig. 5d) . Formyl peptides released from V. harveyi as an indicator for bacterial density were detected by the FPS sensory module of microbial-control-engineered (pFS98/pFS102/pFS84/ pFS186) HEK-293 cells. Designer cells subsequently initiated AI-2 biosynthesis and secretion, directly addressed responsive V. harveyi in the upper compartment and orchestrated bacterial luminescence. The increased V. harveyi bioluminescence confirmed AI-2-mediated inter-species quorum sensing (Fig. 5e, f) .
Finally, the microbial-control device from engineered HEK-293 cells was applied to the opportunistic human fungal pathogen b Microbialcontrol-transgenic pFS98/pFS102/pFS84/pFS186-cotransfected HEK-293 cells were grown for 24 h in cell culture medium adjusted to increasing fMLF levels, before AI-2 activities were profiled (black) and AI-2 concentrations were determined (green) in the culture supernatant. c Impact of fMLF doses and induction time on microbial-control-mediated AI-2 secretion. AI-2 release profile from microbial-control cells exposed to rising fMLF levels and induction pulses after 24 h. AI-2 activity was measured in terms of V. harveyi (MM32) bioluminescence. d Autonomous control of microbial pathogens through microbial-control-engineered cells. Schematic depicts the release of formyl peptides from microbes. Diffusible formyl peptides activate microbial-control cells to release AI-2, which, in turn, induces bacterial bioluminescence or reduces biofilm formation. e, f Microbial-control or mock-engineered HEK-293 cells (Control) were seeded in the lower chamber of a Transwell, and then co-cultivated with V. harveyi AI-2 reporter strain (MM32, luxS -) in the upper compartment. Twenty hours after incubation with mammalian cells, V. harveyi bioluminescence was e imaged and f quantified. g HEK-293 co-transfected with the microbial-control device components or transfected with pcDNA3.1 (Control) were grown in the bottom chamber and then challenged with C. albicans in the upper compartment. After co-cultivation for 24 h, C. albicans biofilm formation was measured by means of MTT assay. Biofilm formation is expressed as a percentage of the control value of C. albicans co-cultivated with HEK-293 control cells lacking the genetic components. Data represent the means ± SD of three independent experiments measured in triplicate. *p < 0.05, ****p < 0.00001, two-tailed Student's t-test C. albicans to test its ability to inhibit biofilm formation, since AI-2 has been reported to inhibit C. albicans biofilm formation in a dose-dependent manner 9 . We used a Transwell setup with a porous filter membrane to separate pathogenic yeast in the upper compartment from adherent microbial-control cells in the bottom compartment while permitting free molecule diffusion (Fig. 5d) . Experimental analysis of microbial-control cells challenged with C. albicans confirmed that biofilm formation of co-cultured C. albicans was substantially reduced by half within 24 h, while control cells failed to inhibit biofilm formation (Fig. 5g) .
AI-2's prophylactic impact on the prevention of microbial biofilms 13 could also be confirmed in follow-up experiments using the opportunistic human pathogen B. cereus (Supplementary Fig. 10a ) and in mixed species communities containing B. cereus as well as E. coli (Supplementary Fig. 10b ).
AI-2-dependent reduction of C. albicans' biofilm formation was most significant during early growth phase ( Supplementary  Fig. 10c ), while AI-2 interventions at higher cell densities had only a modest effect on biofilm formation ( Supplementary  Fig. 10d ). Decreased biofilm formation observed for C. albicans correlated with increased AI-2 secretion from microbial-control engineered cells following exposure to the pathogenic yeast ( Supplementary Fig. 10e ). Control experiments exploring the impact of AI-2-secreting cells on the composition of mixedspecies communities 14 did not reveal significant changes ( Supplementary Fig. 10f ), which is in line with the fact that AI-2 does not shift compositions of native commensal communities in the absence of antibiotics 14 .
Thus, the microbial-control device robustly detected pathogens, coordinated AI-2 release exclusively in response to microbial peptides, and prevented fungal biofilm formation.
Discussion
Synthetic biology enables cell responses to be tailored to a diverse combinatorial repertoire of input signals ranging from small molecules to peptides 57 , but technology for specific detection of microbial invaders has so far only been implemented in prokaryotes 42, 58 . We considered that a two-way communication interface between designer cells and microbes might be applied to reprogram bacterial quorum-sensing-controlled traits with certain precautions, providing an alternative approach to address the issue of microbial resistance to antibiotics. Here, we describe the assembly, characterization and validation of designer cells containing an microbial-control device that senses the presence of microbial peptides and exploits the autonomously produced communication signal AI-2 to influence responsive bacteria and human pathogenic yeast. This cell-based microbial control principle represents a mammalian cell-bacteria communication system and mimics features of host-microbial symbioses vital to human health, such as two-way communication and mutual feedback 59 . Its design was inspired by the recently discovered, though still poorly understood, host-microbe crosstalk that permits pathogens to escape traditional cellular defense mechanisms 11, 60 . Formylated peptides appear to be a consistent indicator of bacterial infections and hence can serve as an efficient input molecule, which is why the microbial-control device is designed to exclusively detect formylated peptides as a proxy for the presence of microbes in the bloodstream and will release nontoxic AI-2 exclusively into the bloodstream. Depending on the amount of formylated peptides present, the AI-2 output level can be fine-tuned to the therapeutically effective range matching the physiological AI-2 levels produced by bacteria 61 communicating via quorum sensing 9, 56 . The engineered interface expands the known inter-kingdom vocabulary consisting of mammalian stress hormones and synthetic inducers 62, 63 to the fully active AI-2 communication signal, and is expected to have the ability to drive global changes in gene expression in bacteria causing systemic infections, but could further impact mixed microbial populations such as those that exist in the gut or the oral cavity 8 .
In regards to multiresistent or chronic infection, a prophylactic cellular implant might remotely monitor and fight the source of infection without establishing the selective pressure resulting in the emergence of drug resistance in current antibiotic treatment schemes 6, 64 . To drive designer cell-based anti-infective implants into a clinical reality, the designer cells need to be implanted inside semi-permeable, autovascularizing and immunoprotective microcontainers, 25, 38 . The designer cells will detect the presence of invading microbes via formylated peptides in the circulation and coordinate expression of native factors that take control over bacterial group behavior in the absence of any selective pressure. With the dramatically increasing prevalence of multidrugresistant human-pathogenic bacteria new anti-infective treatment strategies are urgently needed 42, 65 . The synthetic biology inspired microbial-control device could kick-off new opportunities in future anti-infective therapies. This strategy holds great promise for future clinical applications of the microbial-control cells, for it has already been tested in a human clinical trial 25 .
Importantly, our findings indicate that mammalian cells can synthesize bioactive furanosyl borate diester and other members of the AI-2 family of signaling molecules, and are resistant to the metabolic burden of the by-passed methylation cycle. Thus, there should be opportunities to extend designer cell implants towards the biosynthesis of other secretable small molecules.
Due to the inherent flexibility of both the receptor and the chosen species-independent AI-2 output element, diverse pathogens can be targeted, ranging from prokaryotes to fungi 41 . The remarkable sensitivity of the sensor circuit (0.1 nM) derives from the strong interaction of formyl peptides with their cognate receptor and is compatible with the systemic concentrations of a myriad of closely related formyl peptides upon infection. Once activated, the synthetic sensor cascade dynamically triggers the expression of AI-2 biosynthetic enzymes according to the levels of formylated peptides present, amplifies the input signal and provides strong and long-lasting enzymatic autoinducer release. Also, AI-2 is not expected to be toxic at the levels secreted by the designer cells, since AI-2 exposure is well tolerated by human cells 66 .
The microbial-control device could further be used for (i) AI-2 release from implanted microencapsulated designer cells, (ii) to rapidly redirect bacterial motility and hence, (iii) to precisely target bacterial therapeutics in vivo through AI-2-mediated chemotaxis 3,67 , or (iv) for cell-based AI-2 inhibitor screening. Cellbased assays can identify noncytotoxic and bioavailable compounds accessing the microbial habitat of quorum-sensing pathogens and have already enabled the discovery of antiinfective compounds 65 . Higher-order infection control circuits can be envisioned wherein AI-2-secreting host cells hijack the native quorum-sensing systems of bacteria without interfering with mammalian metabolism or communication. Our approach can address wild-type pathogenic microbes and thus contrasts with previous synthetic biology approaches wherein bacteria had to be artificially manipulated 68 .
Biosensor-based circuits in implanted human designer cells programmed to interface with infection-related molecules and to mitigate microbial colonization may pave the way for nextgeneration antimicrobials in the post-antibiotic era. device consist of (i) a FPS module that detects formylated peptides, such as fMLF, by the corresponding human formylated peptide receptor FPR1 (pFS98 (P SV40 -FPR1-pA; GenBank MF688634), (ii) the adapter protein Gα16, which redirects receptor signaling to the Ca 2+ transduction pathway (pFS102 (P SV40 -Gα16-pA; GenBank MF688633)), (iii) constitutively expressed 5′-methylthioadenosine nucleosidase MTAN (pFS84 (P hCMV -mtaN-pA; GenBank MF688635)) cleaving endogenous SAH and, (iv) the LuxS under the control of a Ca 2 + -responsive promoter (pFS186 (P Ca2 -luxS-pA; GenBank MF688632)) to produce AI-2.
Microbial strains. Escherichia coli strain XL10-Gold ® (XL10-Gold ® ultracompetent cells, Agilent Technologies, Basel, Switzerland; cat. no. 200314) was used for molecular cloning, for microbial composition experiments and plasmid propagation. E. coli strain RP437 (CGSC#: 12122; Coli Genetic Stock Center, Yale, USA) was used for AI-2 accumulation experiments and the ΔLuxS strain DH5α™ (Thermo Fisher, Basel, Switzerland; cat. no. 18265017) for cocultivation experiments. E. coli was grown at 37°C on LB agar plates or in liquid LB medium (Beckton Dickinson, NJ, USA; cat. no. 244610) supplemented with appropriate antibiotics (Ampicillin, 100 µg/mL, cat. no. A9518; Kanamycin, 30 µg/mL, cat. no. K1377, both from Sigma-Aldrich, Munich, Germany 46 were propagated at 30°C in AB-Medium (0.3 M NaCl, 10 mM potassium phosphate, 1 mM L-arginine, 10 mM potassium phosphate, 0.1 mM arginine, 1% glycerol), in case of BB170, TL26 and MM32 supplemented with kanamycin (30 µg/mL). Candida albicans (ATCC: 10231-MINI-PACK) was cultivated in Yeast Extract-Peptone-Dextrose (YPD) medium at 30°C and cell numbers were quantified optically at 600 nm with a Novaspec II photometer (Pharmacia, Freiburg, Germany). P. aeruginosa (PAO1, LasI -, PT466) was grown in LB medium at 37°C. All cells except for Caco-2 and A549 were transfected using an optimized polyethyleneimine (PEI)-based protocol. A transfection solution containing 2 µg of plasmid DNA mixtures, 10 µl PEI (PEI "max", 1 mg/ml in water; Polysciences, Eppelheim, Germany; cat. no. 24765-2) was incubated for 20 min in 800 µl of DMEM at room temperature, then added dropwise to 2.5 × 10 5 cells per well, seeded in a six-well plate the day before transfection. Before seeding, cell number and viability were evaluated using an electric field multi-channel cell counting device (Casy ® Cell Counter and Analyser Model TT; Roche Diagnostics GmbH, Basel, Switzerland). After cotransfection, the culture medium was replaced six hours after transfection for all cell lines (after seven hours for hMSC-TERT). Caco-2 and A549 cells were transfected for 48 h using Lipofectamine 3000/P3000 transfection according to manufacturer's instructions (Thermo Fisher, Basel, Switzerland, cat. no. L3000001).
For the generation of double stable HEK-293-derived cell line HEK-293 sFS26c12 transgenic for simultaneous constitutive P EFIα -driven MTAN and P hCMV -driven LuxS-eYFP expression, 250,000 cells were first transfected with 2000 ng of pFS168 (P EFIα -MTAN) and selected in culture medium containing 20 µg/ml Blasticidin (InvivoGen, San Diego, CA, USA, ant-bl-1) for 2 weeks. Following expansion of single clones by limiting dilution for another 2 weeks and validation of functional MTAN expression, the best performing clone (HEK-293 sFS25c21 ) was co-transfected with 1660 ng of fluorescent S-Ribosylhomocysteinase (LuxS-eYFP; P hCMV -luxSeYFP-pA, pFS169) and 340 ng of the zeocin resistance encoding plasmid pZeoSV2 (+). After 17 days of selection in medium containing 200 µg/ml (w/v) zeocin (Invivogen, San Diego, CA, USA, cat. no. ant-zn-1) and 20 µg/ml Blasticidin, resistant monoclonal cells (HEK-293 sFS26cx ) were obtained by limiting dilution cloning and screened for AI-2 activity in their supernatants. The cell lines were regularly tested for the absence of Mycoplasma.
When generating the triple stable FPS SEAP36 transgenic for simultaneous constitutive P EFIα -driven FPR1, P EFIα -driven G α16 and P Ca2 -driven SEAP expression, 2.4 × 10 5 HEK-293 cells were sequentially engineered by co-transfecting pFS231 (ITR-P Ca2 -SEAP-pA:P RPBSA -ZeoR-pA-ITR), pFS232 (ITR-P hEF1α -FPR1-pA:P RPBSA -BFP-P2A-PuroR-pA-ITR) and pFS233 (ITR-P hEF1α -G α16 -pA:P RPBSA -tdTomato-P2A-BlaR-pA-ITR) with 10% (w/w) of the Sleeping Beauty transposase expression vector pCMV-T7-SB100 (P hCMV -SB100X-pA,), respectively. One day after transfection of pFS231, cells were selected for 10 days in culture medium containing 100 μg/ml zeocin and, after the second transfection (pFS232), for 14 days in culture medium additionally supplemented with puromycin (0.5 µg/ml). Triple stable clones resulting from pFS233 transfection of the double resistant polyclonal cell population were selected for 10 days with blasticidin (10 µg/ml) before stable cell clones were selected for tdTomato and BFP expression by FACS-mediated singlecell cloning. In a second step, the best-performing clone FPS SEAP36 was further engineered with an inducible AI-2 module encoded by pFS274 (ITR-P hCMV -MTAN-pA:P RPBSA -ZeoR-P2A-iRFP-pA-ITR) and pFS285 (ITR-P Ca2 -LuxS-pA: P RPBSA -ZeoR-P2A-eGFP-pA-ITR) and cotransfected with SB transposase vector (pCMV-T7-SB100) before selecting penta-transgenic clones clones FPS AI2-57 via eGFP and iRFP expression using FACS-mediated single-cell cloning.
FACS-mediated cell sorting. The HEK-293 cell subpopulation with top 10% expression of BFP (405 nm laser, 495 nm long-pass filter, 450/50 emission filter), and tdTomato (561 nm laser, 570 nm long-pass filter, 586/15 emission filter) and with top 1% GFP (488 nm laser, 505 nm long-pass filter, 529/28 emission filter) and iRFP expression (640 nm laser, 670 nm long-pass filter, 720/13 emission filter) were sorted using a Becton Dickinson LSRII Fortessa flow cytometer (Becton Dickinson, Allschwil, Switzerland). Dead cells and cell doublets were excluded and untreated HEK-293 cells or parental polyclonal populations served as negative controls.
AI-2 quantification. Cells were cultivated in DMEM (Thermo Fisher, Basel, Switzerland, low glucose, without phenol red, cat. no. 11880-028) supplemented with 4 mM L-glutamine (Thermo Fisher, Basel, Switzerland, cat. no. 25030-024) and 1% FCS without antibiotics for 24 h (unless otherwise stated) and cell-free samples were prepared by centrifuging cell supernatants of transfected cells. To quantify AI-2 levels, a stationary overnight culture of Vibrio (BB120/BB170/ JMH626) was grown in AB-Medium and diluted 1:5000 in sterile AB-Medium, while TL26 was diluted 1:1000. When using the LuxS --deficient MM32 reporter strain, a stationary overnight culture grown in Luria Marine (LM)-medium 11 was diluted 1:500 in AB-Medium and incubated for 1 h at 30°C. Cell culture supernatants (10 µl) were analyzed by adding 90 µl of the respective Vibrio AI-2 reporter strain. Vibrio strains were grown for 3.5 h (BB170, BB120, JMH626), 6 h (MM32) or 8 h (TL26), respectively, in black-bottomed Fluotrac 200 96-well plates (Greiner Bio-One, Frickenhausen, Germany) at 30°C and 200 rpm prior to measuring bioluminescence on a GENios Pro plate reader (TECAN AG, Maennedorf, Switzerland). Integration time was set at 1000 ms. Chemically synthesized DPD was purchased (Omm Scientific, Dallas, Texas, USA) and used as a positive control. Background luminescence of the negative control (AB-medium) was subtracted from samples. The DPD standard curve was calculated using GraphPad Prism 6 (GraphPad Software, CA, USA) and a four parameter logistic fitting.
Sensing of formyl peptides from different microbes. E. coli (XL-10 Gold), P. aeruginosa (PAO1, PT466) and V. harveyi (BB170) in LB medium, C. albicans (ATCC: 10231) and Saccharomyces cerevisiae BY4741 (Euroscarf, Johann Wolfgang von Goethe-University Frankfurt am Main, Germany) in YPD medium, were grown overnight, washed, diluted (1:10) and resuspended in Roswell Park Memorial Institute 1640 culture medium (RPMI; Thermo Fisher, Basel, Switzerland; cat. no. 52400-025) and then grown for 3 h. Supernatants were collected by centrifugation, sterile-filtered and finally added to transiently transfected FPS SEAP cell populations (40% v/v).
Chemical compounds. Amphotericin B (25 mg/mL stock in DMSO SigmaAldrich, cat. no. A2411) was used for inhibition of fungal growth. L-norepinephrine (10 mM stock solution in DMSO; Sigma-Aldrich, cat. no. A7257), acetylcholine chloride (10 mM stock in DMSO, Sigma-Aldrich, cat. no. A2661), fMLF (10 mM stock in DMSO, Sigma-Aldrich, cat. no. 47729), fMIFL (10 mM stock in DMSO, Phoenix Pharmaceuticals, cat. no. 072-05), tBOC (2 mM stock solution in DMSO, Tocris, cat. no. 3730) and human serum (Sigma-Aldrich, cat. no. H4522) were directly added to FPS SEAP -engineered cells.
Microbial biofilm formation assay. We used a modified MTT assay for biofilm quantification 9 of Bacillus cereus, Escherichia coli, and Candida albicans. For testing the effect of exogenous AI-2, microbial strains inoculated (OD 600 = 0.01) in microtiter wells or established C. albicans biofilms (24 h) were treated with in vitro synthetized DPD and biofilms were quantified 24 h later. For co-cultivation experiments, HEK-293 cells were seeded (250,000 cells/well) into the bottom of a Transwell (BD Biosciences, Sparks, MD, USA, cat. no. 353092), and transfected for 6 h before replacing the culture medium (10% FCS). Transwells inlets were placed into a six-well plate containing either mock-transfected control cells or cells harboring the microbial-control device for programmable AI-2 release and filled with 1 ml of medium. At 24 h after transfection, a stationary 24-hour culture of C. albicans grown in YPD medium was washed and resuspended in PBS prior to inoculating the upper Transwell with 400,000 cfu. Following another 24 h of cocultivation, the culture medium in the upper culture chamber was replaced with fresh medium (DMEM, without phenol red) supplemented with MTT solution (Sigma-Aldrich, Munich, Germany; cat. no. M5655) at the final concentration of 0.5 mg/ml. After 1 h of incubation, the supernatants were carefully removed and the MTT dye in the upper chamber was solubilized in 1 ml acidic isopropanol/ Triton mixture (0.1 N HCl, 10% (v/v) Triton X-100) for 15 min. Absorbance of the solubilized MTT dye was quantified optically at 550 nm with 650 nm background subtraction on an InfintePro multi-well reader (TECAN AG, Maennedorf, Switzerland).
Analysis of microbial composition. To verify the effect of AI-secreting cells on the composition of mixed microbial communities, stationary overnight cultures of four microbial strains (C. albicans, E. coli XL10-Gold-pKDT17 (AmpR), V. harveyi MM32 (KanR) and L. reuteri 20016) were washed, normalized to OD 600 = 0.01 and resuspended in AB medium. Engineered HEK-293 cells cultivated in modified DMEM (30% AB medium, 1% FCS) were infected with the microbial consortium (multiplicity of infection of each strain, MOI = 8). After 24 h, culture supernatants containing the microbial populations were serially diluted in LB (10 −1 /10 −6 ) and plated on (semi-)selective agar plates for c.f.u. analysis. Colonies of C. albicans were determined on YPD plates supplemented with Chloramphenicol, E. coli on LB (Ampicillin) and V. harveyi on LB (Kanamycin) agar plates after 20 h at 30°C. L. reuteri colonies were counted from MRS agar Vegitone plates (Sigma-Aldrich, cat. no. 41782) containing amphotericin B (2.5 µg/ml) for 24 h of incubation at 37°C, 8% CO 2 .
Western blot analysis. To check for full length eYFP-fusion protein expression in HEK-293 cells, western blot analysis was performed by resuspending 1 × 10 6 HEK-293 cells in 100 µl RIPA lysis buffer (50 mM Tris-HCl (pH 8), 0.15 M NaCl, 1% (v/ v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS and a cocktail of protease inhibitors (Roche, Mannheim, Germany; cat. no. 11873580001) and constant agitation at 4°C for 30 min. The lysate was cleared from cell debris by centrifugation (4000×g for 10 min at 4°C) and the protein content of the supernatant was quantified (Bio-Rad protein assay; Bio-Rad Laboratories, Hercules, CA, USA; cat. no. 500-0006). Samples of 25 µg protein were mixed with 5× loading buffer (10% SDS, 1 M Tris pH 6.8, 50% glycerol, 0.2% bromphenol blue, 0.5 M DTT), resolved on a 12% SDS-PAGE and electroblotted (Trans-blot SD semi-dry transfer cell; Bio-Rad, Hercules, CA, USA) onto a polyvinylidene fluoride membrane (Immobilon-P, Millipore, Billerica, MA, USA; cat. no. IPVH00010). MTANeYFP and LuxS-eYFP fusions were visualized using a mouse anti-GFP antibody (sc-9996; lot. no. F2212, 1:1000) and a horseradish peroxidase-conjugated antimouse secondary antibody (GE Healthcare, Buckinghamshire, UK; cat. no. NA931V, lot no. 399402, 1:10,000) and ECL Plus Western blotting reagents (Amersham, GE Healthcare, Buckinghamshire, UK; cat. no. RPN2132). β-Actin served as a loading control (primary anti-actin antibody, Sigma-Aldrich, Munich, Germany; cat. no. A2066, lot no. 030M4844, 1:100; secondary horseradish peroxidase-coupled anti-rabbit antibody, AbD Serotec, Oxford, UK; cat. no. STAR54, lot no. 291010, 1:10,000). Chemiluminescence-based signal detection was performed with a Chemilux CCD camera (ImageQuant LAS 400 mini; GE Healthcare).
Bacterial co-cultivation and bioluminescence imaging. V. harveyi and E. coli (DH5α) were grown overnight in LM and LB medium, respectively. Various host cell lines were seeded (63'000 cells/well) into the bottom of a 24-well permeable support companion plate (Corning, Lowell, MA, USA, cat. no. 353504), and transfected overnight. For E. coli infection assays, the culture medium was exchanged with 300 µl of fresh medium (DMEM; Thermo Fisher, Basel, Switzerland; cat. no. 52100-039) supplemented with 10% FCS in the lower compartment, or with 500 µl of fresh medium (DMEM, low Glucose, without phenol red, 1% FCS, 30 µg/ml kanamycin) for Vibrio assays. Transwells inlets (Corning, Lowell, MA, USA, cat. no. 353495) were placed on top of mock-transfected control cells or cells harboring the microbial-control device for programmable AI-2 release and inlets were filled with 0.20 ml containing 8 × 10 6 E. coli CFUs in FCS-supplemented (4%) RPMI (Thermo Fisher, Basel, Switzerland; cat. no. 52400-025) and AI-2 levels in the lower compartment were quantified after 24 h. For Vibrio assays, inlets were filled with 250 µl AB medium spiked with 8 × 10 6 CFU of V. harveyi (MM32). After 20 h of incubation at 30°C, 5% CO 2 , bioluminescence of 100 µl samples taken from the upper compartment containing V. harveyi was quantified in black-bottomed Fluotrac 200 96-well plates (Greiner Bio-One, Frickenhausen, Germany) on a GENios Pro plate reader (TECAN AG, Maennedorf, Switzerland). Integration time was set at 1000 ms. Bioluminescence of the Transwell plate was additionally recorded with a Chemilux CCD camera (ImageQuant LAS 400 mini; GE Healthcare) with 1000 ms integration time.
